Company news

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news

Ironwood Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 3, 2026: Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare…

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news

Press releases & updates

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

EchoStor Technologies Bolsters C-Suite with Appointment of Cale Anjoorian as Chief Information Officer

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results